Nuvalent (NUVL) Profit After Tax (2020 - 2026)
Nuvalent (NUVL) posted Profit After Tax of -$113.0 million for Q1 2026, up 6.74% on a QoQ basis from -$121.2 million in Q4 2025, and down 33.58% year-over-year from -$170.1 million in Q1 2025.
Nuvalent (NUVL) Profit After Tax (2020 - 2026) Analysis & Trends
Nuvalent's Profit After Tax history runs 7 years deep, the most recent figure standing at -$113.0 million for Q1 2026.
- Quarterly Profit After Tax fell 33.58% year-over-year to -$113.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$455.2 million (down 50.64% YoY) and the FY2025 annual result came in at -$425.4 million, down 63.14% from the prior year.
- Profit After Tax was -$113.0 million for Q1 2026 at Nuvalent, up from -$121.2 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$17.5 million in Q1 2022 and bottomed at -$121.4 million in Q3 2025.
- A 5-year average of -$59.4 million and a median of -$44.5 million in 2024 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2022 — Profit After Tax sank 158.64% — and 2026, when it slumped 33.58%.
- Nuvalent's Profit After Tax stood at -$26.1 million in 2022, then slumped by 46.58% to -$38.3 million in 2023, then sank by 98.75% to -$76.1 million in 2024, then plunged by 59.2% to -$121.2 million in 2025, then increased by 6.74% to -$113.0 million in 2026.
- Business Quant data shows NUVL's Profit After Tax at -$113.0 million in Q1 2026, -$121.2 million in Q4 2025, and -$121.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | -112.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -112.99 Mn |
| Dec 31, 2025 | -121.16 Mn |
| Sep 30, 2025 | -121.43 Mn |
| Jun 30, 2025 | -99.65 Mn |
| Mar 31, 2025 | -84.58 Mn |
| Dec 31, 2024 | -76.11 Mn |
| Sep 30, 2024 | -84.35 Mn |
| Jun 30, 2024 | -57.17 Mn |
| Mar 31, 2024 | -44.48 Mn |
| Dec 31, 2023 | -38.29 Mn |
| Sep 30, 2023 | -33.65 Mn |
| Jun 30, 2023 | -29.09 Mn |
| Mar 31, 2023 | -25.19 Mn |
| Dec 31, 2022 | -26.12 Mn |
| Sep 30, 2022 | -19.45 Mn |
| Jun 30, 2022 | -18.47 Mn |
| Mar 31, 2022 | -17.55 Mn |
| Dec 31, 2021 | -17.23 Mn |
| Sep 30, 2021 | -12.45 Mn |
| Jun 30, 2021 | -9.84 Mn |